Apogee Therapeutics, Inc. (APGE)
NASDAQ: APGE · Real-Time Price · USD
37.88
+0.75 (2.02%)
At close: Sep 5, 2025, 4:00 PM
37.12
-0.76 (-2.01%)
After-hours: Sep 5, 2025, 7:41 PM EDT

Apogee Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2024FY 2023FY 2022
Period Ending
Jun '25 Dec '24 Dec '23 Dec '22
Selling, General & Admin
62.849.0124.583.21
Research & Development
208.03167.8768.4230.31
Operating Expenses
270.83216.879333.52
Operating Income
-270.83-216.87-93-33.52
Interest & Investment Income
33.3334.749.020.1
Other Non Operating Income (Expenses)
----9.98
Pretax Income
-237.5-182.13-83.99-43.4
Income Tax Expense
0.170.02--
Net Income
-237.67-182.15-83.99-43.4
Net Income to Common
-237.67-182.15-83.99-43.4
Shares Outstanding (Basic)
5855252
Shares Outstanding (Diluted)
5855252
Shares Change (YoY)
17.27%120.72%915.57%-
EPS (Basic)
-4.12-3.30-3.36-17.63
EPS (Diluted)
-4.12-3.30-3.36-17.63
Free Cash Flow
-226.58-172.33-74.93-17.92
Free Cash Flow Per Share
-3.93-3.12-3.00-7.28
EBITDA
-270.1-216.68--
D&A For EBITDA
0.730.19--
EBIT
-270.83-216.87-93-33.52
Updated Aug 11, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q